

DAFTAR PUSTAKA

- Ahmad, S., Campos, M.G., Fratini, F., Altaye, S.Z., Li. J., 2020, New insights into the biological and pharmaceutical properties of royal jelly. *Int. J. Mol. Sci.* 21 (2): 1–26.
- Ahmed, E.F., El-Baky, R.M.A., Ahmed, A.B.F., Waly, N. G., Gad, G.F. M., 2017., Antibacterial activity of some non-steroidal anti-inflammatory drugs against bacteria causing urinary tract infection., *Am. J. Infect. Dis. Microbiol.* 5 (1): 66–73.
- Alhazmi, A., 2015, *Pseudomonas aeruginosa* – Pathogenesis and Pathogenic Mechanisms, *Int.J.Biol.* 7 (2): 44–67.
- Baker, N R, V Minor, C Deal, M S Shahrabadi, D A Simpson, dan D E Woods., 1991, *Pseudomonas aeruginosa* Exoenzyme S Is an Adhesin, *Infect.Immun.* 59 (9): 2859–63.
- Balai Besar Teknik Kesehatan Lingkungan dan Pengendalian Penyakit Yogyakarta, 2018, *Rencana Aksi Kegiatan BBTCLP Yogyakarta tahun 2015-2019*. Yogyakarta.
- Barben, J, dan J Schmid., 2007, Dental units as infection sources of *Pseudomonas aeruginosa*, *Eur.Respir.J.* 32 (4): 2–3.
- Barbot, V., Robert, A., Rodier, M.H., Imbert, C., 2012, Update on infectious risks associated with dental unit waterlines, *FEMS Immunol Med Microbiol* 65 (2): 196–204.
- Bloodworth, B. C., Harn, C.S., Hock, C.T., Boon, Y.O., 1995, Liquid chromatographic determination of trans-10-hydroxy-2-decenoic acid content of commercial products containing royal jelly, *J. AOAC Int.* 78 (4): 1019–23.
- Bonez, P.C., Rossi, G.G., Bandeira, J.R., Ramos, A.P., Mizdal, C.R., Agertt, V.A., Nora E.S.S.D., dkk., 2017, Anti-biofilm activity of A22 ((S-3, 4-dichlorobenzyl) isothiourea hydrochloride) against *Pseudomonas aeruginosa* : Influence on biofilm formation, motility and bioadhesion, *Microb.Pathog.* 111: 6–13.
- Borgatti, M., Bezzerri, V., Mancini, I., Nicolis, E., Cristina, M., Lampronti, I., dkk, 2007, Induction of IL-6 gene expression in a CF bronchial epithelial cell line by *Pseudomonas aeruginosa* is dependent on transcription factors belonging to the Sp1 superfamily, *Biochem.Biophys.Res.Commun.* 357: 977–83.

- Boukraa, L., 2008, Additive Activity of Royal Jelly and Honey Against *Pseudomonas aeruginosa*, *Altern.Med.Rev.* 13 (4): 330–33.
- Brudzynski, K. dan Sjaarda, C., 2015, Honey glycoproteins containing antimicrobial peptides, jelleins of the Major Royal Jelly Protein 1, are responsible for the cell wall lytic and bactericidal activities of honey, *PLoS ONE.* 10 (4): 1–21.
- Brudzynski, K., Sjaarda, C., dan Lannigan, R., 2015, MRJP1-containing glycoproteins isolated from honey, a novel antibacterial drug candidate with broad spectrum activity against multi-drug resistant clinical isolates, *Front. Microbiol.* 6 (711): 1–9.
- Caldas, R.R., Le Gall, F., Revert K., Rault, G., Virmaux, M., Gouriou, S., Héry-Arnaud, G., Barbier, G., dan Boisramé, S., 2015, *Pseudomonas aeruginosa* and periodontal pathogens in the oral cavity and lungs of cystic fibrosis patients: A case-control study, *J.Clin.Microbiol.* 53 (6): 1898–1907.
- Chai, A. C. dkk, 2015, Ibuprofen regulates the expression and function of membrane-associated serine proteases prostasin and matriptase, *BMC Cancer.* 15(1), pp. 1–14.
- Chen, F., Castranova, V., Shi, X., 2001, New insights into the role of Nuclear Factor-KB in cell growth regulation.” *Am. J. Pathol.* 159 (2): 387–97.
- Chen, S.M., Cheng D., Williams, B.J., Sherrill, T. P., Han, W., Chont, M., Saint-Jean, L., dkk, 2008, The nuclear factor kappa-B pathway in airway epithelium regulates neutrophil recruitment and host defence following *Pseudomonas aeruginosa* infection, *Clin.Exp.Immunol.* 153: 420–28.
- Chen, Yi-Fan, Wang, K., Zhang, Yan-Zheng, Zheng, Yu-Fei dan Hu, Fu-Liang, 2016, In Vitro Anti-Inflammatory Effects of Three Fatty Acids from Royal Jelly, *Mediators Inflamm.* 1–11.
- Chmiel, J.F., dan Konstan, M.W., 2007, Inflammation and Anti-Inflammatory Therapies for Cystic Fibrosis, *Clin.Chest Med.* 28 (2): 331–46.
- Chmiel, J.F., dan Konstan, M.W., dan Elborn, J.S., 2013, Antibiotic and anti-inflammatory therapies for cystic fibrosis, *Cold Spring Harb. Perspect. Med.* 3 (10): 1–17.
- Christman, J.W., Sadikot, R.T., dan Blackwell, T.S., 2000, The Role of Nuclear Factor-k B in Pulmonary Diseases, *Chest.* 117 (5): 1482–87.
- Cole, N., Bao, S., Willcox, M., dan Husband, A.J., 1999, Expression of interleukin-

- 6 in the cornea in response to infection with different strains of *Pseudomonas aeruginosa*, *Infect.Immun.* 67 (5): 2497–2502.
- D'Ovidio, C., Carnevale, A., Pantaleone, G., Piattelli, A., Di Bonaventura, G., 2011, First report of an acute purulent maxillary sinusitis caused by *Pseudomonas aeruginosa* secondary to dental implant placement in an immunocompetent patient, *Br. Dent. J.* 211 (5): 205–7.
- Dahlen, G., 2009, Bacterial infections of the oral mucosa, *Periodontol.* 2000. 49 (1): 13–38.
- Dai, L., Wu, Tian-Qi., Xiong, Yi-Song., Ni, Hong-Bing., Ding, Y., Zhang, Wen-Chen., Chu, Shao-Peng., Ju, Shao-Qing., dan Yu, J., 2019, Ibuprofen-mediated potential inhibition of biofilm development and quorum sensing in *Pseudomonas aeruginosa*, *Life Sci.* 237 (116947): 1–9.
- Droemann, D., Albrecht, D., Gerdes, J., Ulmer, A.J., Branscheid, D., Vollmer, E., Dalhoff, K., Zabel, P., Goldmann, T., 2005, Human lung cancer cells express functionally active toll-like receptor 9, *Respir.Res.* 6.
- Elsisi, N.S., Darling-Reed, S., Lee, E.Y., Oriaku, E.T., dan Soliman, K.F., 2005, Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia, *Neurosci. Lett.* 375: 91–96.
- Elders, K. T., dan Wright, S.J.L., 1995, Antibacterial activity of the anti-inflammatory compound ibuprofen, *Lett.Appl.Microbiol.* 20 (2): 82–84.
- Fratini, F., Cilia, G., Mancini, S., Felicioli, A., 2016, Royal Jelly : An ancient remedy with remarkable antibacterial properties, *Microbiol. Res.* 192: 130–41.
- Fratini, A., Fabbri, M., Valli, R., De Paoli, E., Montalbano, G., Gribaldo, L., Pasquali, F., dan Maserati, E., 2015, High variability of genomic instability and gene expression profiling in different HeLa clones, *Sci. Rep.* 5 (15377): 1-9.
- Fujii, R., Saito, Y., Tokura, Y., K-I, N., Okuda, K., Ishihara, K., 2009, Characterization of bacterial flora in persistent apical periodontitis lesions, *Oral Microbiol. Immunol* 24: 502–5.
- Fujitani, S., Sun, Hsin-Yun., Yu, VL., dan Weingarten, J.A., 2011, Pneumonia due to *Pseudomonas aeruginosa* Part I: Epidemiology, Clinical Diagnosis, and Source, *Chest.* 139 (4): 909–19.
- Furusawa, T., Arai, Y., Kato, K., Ichihara, K., 2016, Quantitative analysis of Apisin, a major protein unique to royal jelly, *Evidence-based Complement. Altern. Med.*, 1–9.
- Gellatly, S.L., dan Hancock, R.E.W., 2013, *Pseudomonas aeruginosa* : new insights

into pathogenesis and host defenses, *Pathog. Dis.* 67: 159–73.

Gendron, R., Grenier, D., Maheu-Robert, L.F., 2000, The oral cavity as a reservoir of bacterial pathogens for focal infections, *Microbes Infect.* 2 (8): 897–906.

Ghosh, S., May, M.J., dan Kopp, E.B., 1998, NF- κ B and Rel Proteins: Evolutionarily Conserved Mediators of Immune Responses, *Annu Rev Immunol.* 16: 225–60.

Gismondi, A., Trionfera, E., Canuti, L., Marco, G.D., Canini, A., 2017, Royal jelly lipophilic fraction induces antiproliferative effects on SH-SY5Y human neuroblastoma cells, *Oncol. Rep.* 38 (3): 1833–44.

Gonçalves-de-Albuquerque, Felipe, C., Silva, A.R., Burth, P., Rocco, P.R.M., Castro-Faria, M.V., dan Castro-Faria-Neto, H.C., 2016, Possible mechanisms of *Pseudomonas aeruginosa*-associated lung disease.” *Int. J. Med. Microbiol.* 306 (1): 20–28.

Greene, C.M., Carroll, T.P., Smith, S.G.J., Taggart, C.C., Devaney, J., Griffin, S., O’Neill, S.J., McElvaney, N.G., 2005, TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells, *J.Immunol.* 174 (3): 1638–46.

Grishin, A. V., Krivozubov, M.S., Karyagina, A.S., Gintsburg, A.L., 2015, *Pseudomonas aeruginosa* lectins as targets for novel antibacterials, *Acta Naturae.* 7 (2): 29–41.

Ha, U., dan Jin, S., 2001, Growth Phase-Dependent Invasion of *Pseudomonas aeruginosa* and Its Survival Within HeLa Cells, *Infect. Immun.* 69 (7): 4398–4406.

Hall, S., Mcdermott, C., Anoopkumar-Dukie, S., Mcfarland, A.J., Forbes, A., Perkins, A.V., Davey, A.K., dkk, 2016, Cellular Effects of Pyocyanin , a Secreted Virulence Factor of *Pseudomonas aeruginosa*, *Toxins (Basel).* 8 (236): 1–14.

Han, E.E., Beringer, P.M., Louie, S.G., Gill, M.A., dan Shapiro, B.J., 2004, Pharmacokinetics of Ibuprofen in Children with Cystic Fibrosis, *Clin Pharmacokinet.* 43 (3): 145–56.

Hartono, S.K., Haniastuti, T., Susilowati, H., Handajani, J., and Jonarta, A.L., 2019, The effect of in vitro royal jelly provision on adhesion of *Pseudomonas Aeruginosa*, *Maj. Kedokt. Gigi Indones.* 5 (1): 1–5.

Hu, F.L., Bíliková, K., Casabianca, H., Daniele, G., Espindola, F.S., Feng, M., Guan, C., dkk., 2019, Standard methods for *Apis Mellifera* royal jelly research,

J. Apic. Res. 58 (2): 1–68.

Imbert, P.R.C., Louche, A., Luizet, Jean-Baptiste., Grandjean, T., Bigot, S., Thomas, E., Gagné, S., dkk, 2017, A *Pseudomonas aeruginosa* TIR Effector Mediates Immune Evasion by Targeting UBAP 1 and TLR Adaptors, *EMBO J.* 1–19.

Jedrzejczak-Silicka, M., 2017, History of Cell Culture, *Intech. Open*, 1–43.

Jensen, P.O., Givskov, M., Bjarnsholt, T., dan Moser, C., 2010, The Immune System vs *Pseudomonas aeruginosa* Biofilms, *FEMS Immunol Med Microbiol.* 59: 292–305.

Jiang, N., Xie, F., Chen, L., Chen, F., Sui, L., 2020, The effect of TLR4 on the growth and local inflammatory microenvironment of HPV-related cervical cancer in vivo, *Infect.Agent.Cancer* 15 (1): 1–10.

Khazaei, M., Ansarian, A., dan Ghanbari, E., 2018, New Findings on Biological Actions and Clinical Applications of Royal Jelly: A Review, *J.Diet.Suppl.* 15 (5): 757–75.

Knouse, M.C., Madeira, R.G., Celani, V.J, 2002, *Pseudomonas aeruginosa* causing a right carotid artery mycotic aneurysm after a dental extraction procedure, *Mayo Clin Proc.* 77 (10): 1125–30.

Kocot, J., Luchowska-Kocot, D., Kurzepa, J., dan Musik, I., 2018, Antioxidant Potential of Propolis , Bee Pollen , and Royal Jelly : Possible Medical Application, *Oxid. Med. Cell. Longev.* 1–29.

Konstan, M.W., 2008, Ibuprofen Therapy for Cystic Fibrosis Lung Disease: Revisited, *Curr. Opin. Pulm. Med.* 14 (6): 567–73.

Konstan, M.W., Krenicky, J.E., Finney, M.R., Kirchner, H.L., Hilliard, K.A., Hilliard, J.B., Davis, P.B., dan Hoppel, C.L., 2003, Effect of Ibuprofen on Neutrophil Migration in Vivo in Cystic Fibrosis and Healthy Subjects, *J. Pharmacol. Exp. Ther.* 306 (3): 1086–91.

Konstan, M.W., Schluchter, M.D., Xue, W., dan Davis, P.B., 2007, Clinical Use of Ibuprofen is Associated with Slower FEV1 Decline in Children with Cystic Fibrosis, *Am. J. Respir.Crit.Care Med.* 176 (11): 1084–89.

Landry, J.J.M., Pyl, P.T., Rausch, T., Zichner, T., Tekkedil, M.M., Stütz, A.M., Jauch, A., dkk, 2013, The Genomic and Transcriptomic Landscape of a HeLa Cell Line, *Genes Genomes Genet.* 3 (August): 1213–24.

Lands, L.C., Milner, R., Cantin, A.M., Manson, D., dan Corey, M., 2007, High-

- Dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial, *J. Pediatr.* 151 (3): 249–54.
- Lavoie, E.G., Wangdi, T., dan Kazmierczak, B.I., 2011, Innate Immune Response to *Pseudomonas aeruginosa* Infection, *Microbes Infect.* 13 (14–15): 1133–45.
- Lawrence, T., 2009, The Nuclear Factor NF- κ B Pathway in Inflammation, *Cold Spring Harb Perspect Biol.* 1: 1–10.
- Legrand-Poels, S., Schoonbroodt, S., Piette, J., 2000, Regulation of Interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line.” *Biochem. J.* 349 (3): 765–73.
- Lerrer, B., Zinger-Yosovich, K.D., Avrahami, B., dan Gilboa-Garber, N., 2007, Honey and royal jelly, like human milk, abrogate lectin-dependent infection-preceding *Pseudomonas aeruginosa* adhesion, *ISME J.* 1 (2): 149–55.
- Li, L., Cheng, F.W., Wang, F., Jia, B., Luo, X., dan Zhang, S.Q., 2014, The Activation of TLR7 Regulates the Expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells, *Mol. Cell. Biochem.* 389 (1–2): 43–49.
- Libermann, T.A. dan Baltimore, D., 1990, Activation of Interleukin-6 Gene Expression through the NF-KB Transcription Factor, *Mol. Cell. Biol.* 10 (5): 2327–34.
- Lin, C.K. dan Kazmierczak, B.I., 2017, Inflammation : A Double-Edged Sword in the Response to *Pseudomonas aeruginosa* Infection, *J Innate Immun.* 9 (3): 250–61.
- Lin, N., Chen, S., Zhang, H., Li, J., Fu, L., 2018, Quantification of major royal jelly protein 1 in fresh royal jelly by ultraperformance liquid chromatography – tandem mass spectrometry, *J. Agric. Food Chem.* 66: 1270–78.
- Lin, Y., Zhang, M., Wang, L., Lin, T., Wang, G., Peng, J., Su, S., 2020, The in vitro and in vivo wound-healing effects of royal jelly derived from *Apis Mellifera L.* during blossom seasons of *Castanea Mollissima Bl.* and *Brassica Napus L.* in South China exhibited distinct patterns, *BMC Complement. Med. Ther.* 20 (1): 1–13.
- Liu, T., Zhang, L., Joo, D., dan Sun, Shao-Cong., 2017, NF- κ B Signaling in Inflammation, *Signal Transduct. Target. Ther.* 2: 1–9.
- Louis, KS dan Siegel, AC. Mammalian cell viability : methods and protocols biology. In: *Methods in Molecular Biology* [Internet]. 2011. 740: 7-12.

- Luo, Y. dan Zheng, S.G., 2016, Hall of Fame among Pro-inflammatory Cytokines : Interleukin-6 Gene and its Transcriptional Regulation Mechanisms, *Front. Immunol.* 7 (December): 1–7.
- Manrique-Moreno, M., Villena, F., Sotomayor, C.P., Edwards, A.M., Muñoz, M.A., Garidel, P., Suwalsky, M., 2011, Human cells and cell membrane molecular models are affected in vitro by the nonsteroidal anti-inflammatory drug ibuprofen.” *Biochim. Biophys. Acta – Biomembr.* 1808 (11): 2656–64.
- McIsaac, S.M., Stadnyk, A.W., Lin, T.J., 2012, Toll-like receptors in the host defense against *Pseudomonas aeruginosa* respiratory infection and cystic fibrosis, *J.Leukoc.Biol.* 92 (5): 977–85
- Mogensen, T.H., 2009, Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses, *Clin.Microbiol. Rev.* 22 (2): 240–73.
- Mureşan, C. I. dan Buttstedt, A., 2019, PH-dependent stability of honey bee (*Apis Mellifera*) major royal jelly proteins, *Sci. Rep.* 9 (1): 3–8.
- Musa, M., Nasir, NFM., Thirumulu, KP., 2014, Evaluation of royal jelly as an alternative to fetal bovine serum in cell culture using cell proliferation assays and live cell imaging, *African J. Tradit. Complement. Altern. Med.* 11 (1): 148–55.
- Nakamoto, K., Watanabe, M., Sada, M., Inui T., Honda, K., Wada, H., Ishii, H., dan Takizawa, H., 2019, *Pseudomonas aeruginosa* -derived Flagellin Stimulates IL-6 and IL-8 Production in Human Bronchial Epithelial Cells : A Potential Mechanism for Progression and Exacerbation of COPD, *Exp. Lung Res.* 1–12.
- Okahashi, N., Sumitomo, T., Nakata, M., Sakurai, A., dan Kuwata, H., 2014, Hydrogen Peroxide Contributes to the Epithelial Cell Death Induced by the Oral Mitis Group of Streptococci, *PLoS ONES.* 9 (1): 1–7.
- Ozaki, M., Miyake, Y., Shirakawa, M., Takemoto, T., Okamoto, H., dan Suginaka, H., 1990, Binding Specificity of *Fusobacterium nucleatum* to Human Erythrocytes, Polymorphonuclear Leukocytes, Fibroblast, and HeLa cells, *J. Periodontal Res.* 25 (3): 129–34.
- Pasupuleti, V.R., Sammugam, L., Ramesh, N., dan Gan, S.H., 2017, Honey , Propolis , and Royal Jelly : A Comprehensive Review of Their Biological Actions and Health Benefits, *Oxid. Med. Cell. Longev.* 1–21.
- Pereira, R. S., Bonardi, J.P., Ferreira, A. C.D., Latini, G. L., 2017, An unusual case of dental infection by *Pseudomonas aeruginosa* causing a brain abscess: case report, *Aust. Dent. J.* 62 (4): 523–27.

- Pier, G.B., 2007, *Pseudomonas aeruginosa* Lipopolysaccharide : A Major Virulence Factor, Initiator of Inflammation and Target for Effective Immunity, *J. Med. Microbiol.* 297: 277–95.
- Pistollic, J., Cosseau, C., Li, Y., Yu, J., Filewod, N.C.J., Gellatly, S., Rehaume, L.M., Bowdish, D.M.E., dan Hancock, R.E.W., 2009, Host Defence Peptide LL-37 Induces IL-6 Expression in Human Bronchial Epithelial Cells by Activation of the NF- κ B Signaling Pathway, *J. Innate Immun.* 1 (3): 254–67.
- Rainsford, K.D., 2009, Ibuprofen: pharmacology, efficacy and safety, *Inflammopharmacology.* 17 (6): 275–342.
- Rocca, J., Manin, S., Hulin, A., Aissat, A., Verbecq-Morlot, W., Prulière-Escabasse, V., Wohlhuter-Haddad, A., Epaud, R., Fanen, P., Tarze, A., 2016, New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis, *Br. J Pharmacol.* 173 (11): 1728–41.
- Ross, N.W., Levitan, R., Labelle, J., Schneider, H., 1991, Protein and other compositional differences of the extracellular material from slimy and non-slimy colonies of non-mucoid *Pseudomonas aeruginosa*, *FEMS Microbiol. Lett.* 81 (3): 257–60.
- Ruffin, M., dan Brochiero, E., 2019, Repair Process Impairment by *Pseudomonas aeruginosa* in Epithelial Tissues : Major Features and Potential Therapeutic Avenues, *Front. Cell. Infect. Microbiol.* 9 (May): 1–18.
- Rymut, S. M. dkk, 2016, Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells, *Am. J. Physiol. - Lung Cell. Mol. Physiol.* 311(2), pp. 317–327.
- Sadikot, R.T., Blackwell, T.S., Christman, J.W., dan Prince, A.S., 2005, State of the Art Pathogen – Host Interactions in *Pseudomonas aeruginosa* Pneumonia Respiratory Infections, *Am J Respir Crit Care Med.* 171: 1209–23.
- Schmittgen, T.D., dan Livak, K.J., 2008, Analyzing Real-Time PCR Data by the Comparative CT Method, *Nat. Protoc.* 3 (6): 1101–8.
- Sedlak-Weinstein, E., Cripps, A.W., Kyd, J.M., dan Foxwell, A.R., 2005, *Pseudomonas aeruginosa*: The Potential to Immunise Against Infection.” *Expert Opin. Biol. The.* 5 (7): 967–82.
- Shah, P.N., Marshall-Batty, K.R., Smolen, J.A., Tagaev, J.A., Chen, Q., Rodesney, C.A., Le, H.H., Gordon, V.D., Greenberg, D.E., dan Cannon, C.L., 2018, Antimicrobial Activity of Ibuprofen Against Cystic Fibrosis-Associated Gram-Negative Pathogens, *Antimicrobial.* 62 (3): 1–22.
- Siqueira, Jr., José, F., Rôças. I.N., 2008, Clinical Implications and Microbiology of

- Bacterial Persistence after Treatment Procedures, *J.Endod.* 34 (11): 1291–1301e3.
- Sugiyama, T., Ta, K., dan Mori, H., 2012, Royal Jelly Acid , 10-Hydroxy- trans -2-Decenoic Acid , as a Modulator of the Innate Immune Responses, *Endocrine, Metab. Immune Disord:Targets.* 12: 368–76.
- Sugiyama, T., Takahashi, K., Tokoro, S., Gotou, T., Neri, P., dan Mori, H.. 2011, Inhibitory Effect of 10-Hydroxy- Trans -2- Decenoic Acid on LPS-Induced IL-6 Production via Reducing IκB- Alfa Expression, *Innate Immun.* 18 (3): 429–37.
- Sun, H.Y., Fujitani, S., Quintiliani, R., Yu, V.L., 2011, Pneumonia Due to *Pseudomonas Aeruginosa* Part II: Antimicrobial Resistance, Pharmacodynamic Concepts, and Antibiotic Therapy, *Chest.* 139 (5): 1172–85.
- Susilowati, H., Murakami, K., Yumoto, H., Amoh, T., Hirao, K., Hirota, K., Matsuo, T., dan Miyake, Y., 2017, Royal Jelly Inhibits *Pseudomonas aeruginosa* Adherence and Reduces Excessive Inflammatory Responses in Human Epithelial Cells, *Biomed Res. Int.* 1–10.
- Tada, A., dan Hanada, N., 2010, Opportunistic Respiratory Pathogens in the Oral Cavity of the Elderly, *FEMS Immunol Med Microbiol.* 60: 1–17.
- Tallant, T., Deb, A., Kar, N., Lupica, J., De Veer, M.J., DiDonato, J.A., 2004, Flagellin Acting via TLR5 Is the Major Activator of Key Signaling Pathways Leading to NF-κB and Proinflammatory Gene Program Activation in Intestinal Epithelial Cells, *BMC Microbiology* 4: 1–24.
- Tanaka, T., Narazaki, M., dan Kishimoto, T., 2014, IL-6 in Inflammation, Immunity, and Disease, *Cold Spring Harb. Perspect. Biol.* 6: 1–16.
- Tolker-Nielsen, T., 2014, *Pseudomonas aeruginosa* Biofilm Infections : from Molecular Biofilm Biology to New Treatment Possibilities, *Acta Pathol. Microbiol. Immunol. Scand.* 122 (December).
- Toté, K., Berghe, D.V., Deschacht, M., Wit, K.D., Maes, L., Cos, P., 2009, Inhibitory efficacy of various antibiotics on matrix and viable mass of *Staphylococcus aureus* and *Pseudomonas aeruginosa* biofilms, *Int. J. Antimicrob Agents* 33: 525–31.
- Vesna, A., 2018, Focal Infections in Oral Cavity, *J. Dent. Oral. Heal* 4 (2): 1–2.
- Vrane, J., Tje, D., dan Kru, V., 2004, Adherence Ability of *Pseudomonas aeruginosa* Strains Isolated from Patients with Cystic Fibrosis to Two Different Epithelial Cell Lines, *Coll. Antropol* 28 (2): 675–80.

- Wagner, S., Sommer, R., Hinsberger, S., Lu, C., Hartmann, R.W., Empting, M., dan Titz, A., 2016, Novel Strategies for the Treatment of *Pseudomonas aeruginosa* Infections.” *J. Med. Chem.* 59: 5929–69.
- Wei, L.H., Kuo, M.L., Chen, C.A., Chou, C.H., Cheng, W.F., Chang, M.C., Su, J.L., Hsieh, C.Y., 2001, The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway, *Oncogene* 20 (41): 5799–809.
- Yang, Y.C., Chou, W.M., Widowati, D.A., Lin, I.P., Peng, C.C., 2018, 10-Hydroxy-2-decenoic acid of royal jelly exhibits bactericide and anti-inflammatory activity in human colon cancer cells, *BMC Complement. Altern. Med.* 18 (1): 1–7.
- Yi, B., Hu, X., Zhang, H., Huang, J., Liu, J., Hu, J., Li, W., dan Huang, L., 2014, Nuclear NF- κ B p65 in peripheral blood mononuclear cells correlates with urinary MCP-1, RANTES and the Severity of Type 2 Diabetic Nephropathy, *PLoS ONE* 9 (6): 1–7.
- You, Meng-Meng, Chen, Yi-Fan., Pan, Yong-Ming., Liu, Yi-Chen., Tu, J., Wang, K., dan Hu, Fu-Liang, 2018, Royal Jelly Attenuates LPS-Induced Inflammation in BV-2 Microglial Cells through Modulating NF- κ B and p38 / JNK Signaling Pathways, *Mediators Inflamm.* 1–11.
- Zhang, J., Wu, Xin-Yi., dan Yu, Fu-Shin X, 2005, Inflammatory Responses of Corneal Epithelial Cells to *Pseudomonas aeruginosa* Infection, *Curr Eye Res.* 30 (7): 527–34.
- Zowalaty, M.E. dan Gyetvai, B., 2016, Effectiveness of Antipseudomonal Antibiotics and Mechanisms of Multidrug Resistance in *Pseudomonas aeruginosa*, *Polish J. Microbiol.* 65 (1): 23–32.